Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Carisma Therapeutics ( (CARM) ) has shared an announcement.
Carisma Therapeutics Inc. announced a revised operating plan, including a significant workforce reduction of 34%, affecting areas like R&D and finance, and the termination of CFO Richard Morris. The company is halting development of its HER2-targeting CT-0525 due to competitive pressures, pivoting towards mRNA/lipid nanoparticle CAR-M programs with ModernaTX Inc., and exploring treatments for fibrosis and neurodegeneration. These changes aim to streamline operations and focus on promising therapeutic areas.
Find detailed analytics on CARM stock on TipRanks’ Stock Analysis page.
